Circle Pharma, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2024 | $92 M | No. 4 | $50 to $250 million | equity | SEC | |
| Jun 2021 | $66 M | No. 3 | $50 to $250 million | equity | SEC | |
| Mar 2020 | $15 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Sep 2016 | $4 M | No. 1 | $2 to $10 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Circle Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).
SEC Form D · Jan 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2025
That is all the official record says: Circle Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Circle Pharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 20 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David J. Earp | Executive officer | Jan 2025 |
| Paul H. Park | Executive officer | Jan 2025 |
| David Earp | Executive officer | Mar 2022 |
| Elton Satusky | Executive officer | Mar 2022 |
| Cayla J. McEwen | Executive officer | Mar 2020 |
| Elton J. Satusky | Executive officer | Mar 2020 |
| David J. Earp | Director | Jan 2025 |
| James H. Evangelista | Director | Jan 2025 |
| John Josey | Director | Jan 2025 |
| Matthew P. Jacobson | Director | Jan 2025 |
| Stephen H. Kelsey | Director | Jan 2025 |
| Thilo H. Schroeder | Director | Jan 2025 |
| Walter H. Moos | Director | Jan 2025 |
| David Earp | Director | Mar 2022 |
| James Evangelista | Director | Mar 2022 |
| Matthew Jacobson | Director | Mar 2022 |
| Thilo Schroeder | Director | Mar 2022 |
| Walter Moos | Director | Mar 2022 |
| Peter Svennilson | Director | Jun 2021 |
| John P. Josey | Director | Mar 2020 |
| Peter P. Svennilson | Director | Mar 2020 |
| Thilo P. Schroeder | Director | Mar 2020 |
| Walter P. Moos | Director | Mar 2020 |
| Douglas R. Crawford | Director | Sep 2016 |
| Matthew J. Jacobson | Director | Sep 2016 |
| Scott R. Lokey | Director | Sep 2016 |
| Walter R. Moos | Director | Sep 2016 |